XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication – XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South… CISION PRNewswireMarch 2, 2026
Firmable Raises $14m Series A to Take AI-Native Sales Platform Global MELBOURNE, Australia, March 2, 2026 /PRNewswire/ — Firmable, Asia-Pacific’s leading AI (artificial… CISION PRNewswireMarch 2, 2026
Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis SHANGHAI, HANGZHOU, China and BOSTON, March 2, 2026 /PRNewswire/ — Lynk Pharmaceuticals… CISION PRNewswireMarch 2, 2026
Press Release Toku Reports US$34.8 million Revenue in FY2025 as AI Adoption Gains Traction; Underlying Loss Improves SINGAPORE, March 2, 2026 /PRNewswire/ — Toku Ltd. ("Toku", "投酷有限公司" or the… CISION PRNewswireMarch 2, 2026
Understanding China's whole-process people's democracy BEIJING, March 2, 2026 /PRNewswire/ — A report from People’s Daily: The… CISION PRNewswireMarch 2, 2026
Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma SAN FRANCISCO and SUZHOU, China, March 2, 2026 /PRNewswire/ — Innovent Biologics,… CISION PRNewswireMarch 2, 2026
Investor Education Webinar The Future of Prostate Imaging: What do physicians want? MELBOURNE, Australia and… CISION PRNewswireMarch 2, 2026
Press Release Trip.com's Go Explore Mega Sale Set to Launch – Save on Flights, Hotels, Tours & More SYDNEY, March 2, 2026 /PRNewswire/ — Trip.com’s Go Explore Mega Sale is… CISION PRNewswireMarch 2, 2026
